Droxinostat

Selective HDAC inhibitor CAS# 99873-43-5

Droxinostat

2D Structure

Catalog No. BCC2157----Order now to get a substantial discount!

Product Name & Size Price Stock
Droxinostat: 5mg $58 In Stock
Droxinostat: 10mg Please Inquire In Stock
Droxinostat: 20mg Please Inquire Please Inquire
Droxinostat: 50mg Please Inquire Please Inquire
Droxinostat: 100mg Please Inquire Please Inquire
Droxinostat: 200mg Please Inquire Please Inquire
Droxinostat: 500mg Please Inquire Please Inquire
Droxinostat: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Droxinostat

3D structure

Package In Stock

Droxinostat

Number of papers citing our products

Chemical Properties of Droxinostat

Cas No. 99873-43-5 SDF Download SDF
PubChem ID 568416 Appearance Powder
Formula C11H14ClNO3 M.Wt 243.69
Type of Compound N/A Storage Desiccate at -20°C
Synonyms NS 41080
Solubility DMSO : ≥ 150 mg/mL (615.54 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide
SMILES CC1=C(C=CC(=C1)Cl)OCCCC(=O)NO
Standard InChIKey JHSXDAWGLCZYSM-UHFFFAOYSA-N
Standard InChI InChI=1S/C11H14ClNO3/c1-8-7-9(12)4-5-10(8)16-6-2-3-11(14)13-15/h4-5,7,15H,2-3,6H2,1H3,(H,13,14)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Droxinostat

DescriptionDroxinostat is a selective inhibitor of HDAC with IC50 values of 2.47 μM and 1.46 μM for HDACs 6 and 8, respectively.
TargetsHDAC8HDAC6HDAC3HDAC1HDAC2  
IC501.46 μM2.47 μM16.9 μM>20 μM>20 μM  

Droxinostat Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Droxinostat Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Droxinostat

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.1036 mL 20.5179 mL 41.0357 mL 82.0715 mL 102.5894 mL
5 mM 0.8207 mL 4.1036 mL 8.2071 mL 16.4143 mL 20.5179 mL
10 mM 0.4104 mL 2.0518 mL 4.1036 mL 8.2071 mL 10.2589 mL
50 mM 0.0821 mL 0.4104 mL 0.8207 mL 1.6414 mL 2.0518 mL
100 mM 0.041 mL 0.2052 mL 0.4104 mL 0.8207 mL 1.0259 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Droxinostat

Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8 with IC50 value of 16.9 ± 5.0 μM, 2.47 ± 1.09 μM, and 1.46 ± 0.11 μM, respectively [1].

HDACs (histone deacetylases) are enzymes responsible of the deacetylation of lysine that residues of core histones and play a pivotal role in controlling chromatin remodeling and transcriptional activation. It is also reported that HDACs control the acetylation and activation status of multiple non-histone proteins, including the heat shock protein 90 (Hsp90) which is an essential molecular chaperone for fungal virulence and antifungal resistance. Multiple HDACs have been identified and HDAC1 to HDAC10 are shown to express in malignant cells which reminds the HDAC inhibitor as a target for cancer therapy [2] [3].

Droxinostat is a selective HDAC inhibitor and is different from the known pan-HDACi TSA which inhibits all tested HDAC. When tested with prostate cancer line PPC-1 cells, droxinostat treatment selectively inhibited HDAC3, HDAC6, and HDAC8 activity at the concentration of 50 μM/L which sensitized cells to death ligands [1]. In androgen-dependent CaP cells, administration of droxinostat selectively inhibited HDACs and downregulated c-FLP expression which resulted in cells apoptosis [4].

References:
[1].  Wood, T.E., et al., Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther, 2010. 9(1): p. 246-56.
[2].  Lamoth, F., P.R. Juvvadi, and W.J. Steinbach, Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis. Front Microbiol, 2015. 6: p. 96.
[3].  Mackmull, M.T., et al., Histone deacetylase inhibitors cause the selective depletion of bromodomain containing proteins. Mol Cell Proteomics, 2015.
[4].  McCourt, C., et al., Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res, 2012. 18(14): p. 3822-33.

Featured Products
New Products
 

References on Droxinostat

Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.[Pubmed:26947884]

Transl Oncol. 2016 Feb;9(1):70-78.

BACKGROUND: The current chemotherapeutic outcomes for hepatocellular carcinoma (HCC) are not encouraging, and long-term survival of this patient group remains poor. Recent studies have demonstrated the utility of histone deacetylase inhibitors that can disrupt cell proliferation and survival in HCC management. However, the effects of Droxinostat, a type of histone deacetylase inhibitor, on HCC remain to be established. METHODS: The effects of Droxinostat on HCC cell lines SMMC-7721 and HepG2 were investigated. Histone acetylation and apoptosis-modulating proteins were assessed via Western blot. Proliferation was examined with 3-(4, 5 dimetyl-2-thiazolyl)-2, 5-diphenyl 2H-tetrazolium bromide, cell proliferation, and real-time cell viability assays, and apoptosis with flow cytometry. RESULTS: Droxinostat inhibited proliferation and colony formation of the HCC cell lines examined. Hepatoma cell death was induced through activation of the mitochondrial apoptotic pathway and downregulation of FLIP expression. Droxinostat suppressed histone deacetylase (HDAC) 3 expression and promoted acetylation of histones H3 and H4. Knockdown of HDAC3 induced hepatoma cell apoptosis and histone H3 and H4 acetylation. CONCLUSIONS: Droxinostat suppresses HDAC3 expression and induces histone acetylation and HCC cell death through activation of the mitochondrial apoptotic pathway and downregulation of FLIP, supporting its potential application in the treatment of HCC.

Description

Droxinostat(NS41080) is a selective inhibitor of HDAC3, HDAC6, and HDAC8 with IC50 of 16.9, 2.47 and 1.46 μM, respectively; > 8-fold selective against HDAC3 and no inhibition to HDAC1, 2, 4, 5, 7, 9, and 10.

Keywords:

Droxinostat,99873-43-5,NS 41080,Natural Products,HDAC, buy Droxinostat , Droxinostat supplier , purchase Droxinostat , Droxinostat cost , Droxinostat manufacturer , order Droxinostat , high purity Droxinostat

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: